logo
logo

Juvenescence acquires Ro5 to enhance AI drug discovery

Jun 09, 2025•about 1 month ago

Acquiring Company

Juvenescence

Acquired Company

Ro5

RamseyLondonBiotechnologyMachine LearningArtificial IntelligenceBiotechnology

Description

Juvenescence has acquired drug discovery firm Ro5 to enhance its AI and machine learning capabilities in drug discovery. This acquisition is pivotal for Juvenescence's partnership with the global healthcare company M42. The collaboration aims to accelerate the development of therapeutics targeting age-related diseases. Ro5's extensive AI Chemistry Platform will bolster Juvenescence's research and development efforts.

Company Information

Company

Juvenescence

Location

Ramsey, Isle of Man, United Kingdom

About

Juvenescence is a biotechnology company focused on developing therapies aimed at extending healthy lifespan. The company utilizes AI and machine learning in its drug discovery process. It has partnerships with leading healthcare firms to accelerate its development portfolio. Juvenescence aims to target age-related diseases through innovative therapeutic solutions.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Yehudah hidden

hidden

Richard hidden

David hidden

hidden